Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Neurol.

Sec. Artificial Intelligence in Neurology

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1615523

This article is part of the Research TopicTechnology Developments and Clinical Applications of Artificial Intelligence in Neurodegenerative DiseasesView all 8 articles

Harnessing Artificial Intelligence for Brain Disease: Advances in Diagnosis, Drug Discovery, and Closed-Loop Therapeutics

Provisionally accepted
Su-Jun  FangSu-Jun Fang1,2Zhao-Di  YinZhao-Di Yin3Qi  CaiQi Cai4Li-Fan  LiLi-Fan Li1PengFei  ZhengPengFei Zheng5Lizhen  ChenLizhen Chen1,2*
  • 1The First Hospital of Putian City, Putian, China
  • 2Putian University, Putian, Fujian Province, China
  • 3Peking University People's Hospital, Beijing, Beijing Municipality, China
  • 4Nankai University, Tianjin, China
  • 5University of Science and Technology of China, Hefei, Anhui Province, China

The final, formatted version of the article will be published soon.

Brain diseases pose a significant global health challenge due to their complexity and the limitations of traditional medical strategies. Recent advancements in artificial intelligence (AI), especially deep learning models like Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), and Graph Neural Networks (GNNs), offer powerful new tools for analysis. These neural networks are effective at extracting complex patterns from high-dimensional data. By integrating diverse data sources-such as neuroimaging, multi-omics, and clinical information-multimodal AI provides the comprehensive view needed to understand intricate disease mechanisms.This review outlines how these technologies enhance precision drug development and enable closed-loop treatment systems for brain disorders. Key applications include improving diagnostic accuracy, identifying novel biomarkers, accelerating drug discovery through target identification and virtual screening, and predicting patient-specific treatment responses. These AI-driven methods have the potential to shift medicine from a one-size-fits-all model to a personalized approach, with diagnostics and therapies tailored to individual profiles. However, realizing this potential requires addressing significant challenges related to data access, model interpretability, clinical validation, and practical integration.

Keywords: Brain Diseases, artificial intelligence, Drug Discovery, personalized medicine, closed-loop system

Received: 21 Apr 2025; Accepted: 08 Jul 2025.

Copyright: © 2025 Fang, Yin, Cai, Li, Zheng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lizhen Chen, The First Hospital of Putian City, Putian, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.